

1 A Fully Automatic Deep Learning System for COVID-19 Diagnostic and 2 Prognostic Analysis

3 **Authors:** Shuo Wang¹⁺, Yunfei Zha²⁺, Weimin Li³⁺, Qingxia Wu⁴⁺, Xiaohu Li⁵⁺, Meng Niu⁶⁺,
4 Meiyun Wang⁷⁺, Xiaoming Qiu^{8,+}, Hongjun Li^{9,+}, He Yu³, Wei Gong², Yan Bai⁷, Li Li⁹, Yongbei Zhu¹,
5 Liusu Wang¹, Jie Tian^{1,10*}

6 Affiliations:

7 1. Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, School of Medicine
8 and Engineering, Beihang University, Beijing, 100191, China.

9 2. Department of Radiology, Renmin Hospital of Wuhan University, Hubei, 430060, China.

10 3. Department of respiratory and critical care medicine, West China hospital of Sichuan University,
11 Sichuan, 610041, China.

12 4. College of Medicine and Biomedical Information Engineering, Northeastern University,
13 Shenyang, Liaoning 110819, China.

14 5. Department of Radiology, the First Affiliated Hospital of Anhui Medical University, Anhui
15 230022, China.

16 6. Department of Interventional Radiology, the First Hospital of China Medical University, Liaoning
17 110001, China.

18 7. Department of Medical Imaging, Henan Provincial People's Hospital & the People's Hospital of
19 Zhengzhou University, Zhengzhou 450003, Henan, China.

20 8. Department of Radiology, Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic
21 University, Edong Healthcare Group, Hubei, 435000, China.

22 9. Department of Radiology, Beijing Youan Hospital, Capital Medical University, Beijing, 100069,
23 China.

24 10. CAS Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of
25 Sciences, Beijing, 100190, China.

26 + contribute equally.

1 **Corresponding author:**

2 Jie Tian, PhD

3 Fellow of IAMBE, AIMBE, ISMRM, IEEE, SPIE, OSA, IAPR

4 Director of CAS Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of

5 Sciences, Beijing 100190, China;

6 Phone: 86-010-82618465; Fax: 86-010-82618465; E-mail: jie.tian@ia.ac.cn

7

1 **Abstract**

2 Coronavirus disease 2019 (COVID-19) has spread globally, and medical
3 resources become insufficient in many regions. Fast diagnosis of COVID-19, and
4 finding high-risk patients with worse prognosis for early prevention and medical
5 resources optimization is important. Here, we proposed a fully automatic deep
6 learning system for COVID-19 diagnostic and prognostic analysis by routinely used
7 computed tomography.

8 We retrospectively collected 5372 patients with computed tomography images
9 from 7 cities or provinces. Firstly, 4106 patients with computed tomography images
10 and gene information were used to pre-train the DL system, making it learn lung
11 features. Afterwards, 1266 patients (924 with COVID-19, and 471 had follow-up for
12 5+ days; 342 with other pneumonia) from 6 cities or provinces were enrolled to train
13 and externally validate the performance of the deep learning system.

14 In the 4 external validation sets, the deep learning system achieved good
15 performance in identifying COVID-19 from other pneumonia (AUC=0.87 and 0.88)
16 and viral pneumonia (AUC=0.86). Moreover, the deep learning system succeeded to
17 stratify patients into high-risk and low-risk groups whose hospital-stay time have
18 significant difference ($p=0.013$ and 0.014). Without human-assistance, the deep
19 learning system automatically focused on abnormal areas that showed consistent
20 characteristics with reported radiological findings.

21 Deep learning provides a convenient tool for fast screening COVID-19 and
22 finding potential high-risk patients, which may be helpful for medical resource
23 optimization and early prevention before patients show severe symptoms.

24

1 **Keywords:** Coronavirus disease 2019 (COVID-19), deep learning, diagnosis,
2 prognosis, artificial intelligence, computed tomography.

3

4 **Take-home message:** Fully automatic deep learning system provides a convenient
5 method for COVID-19 diagnostic and prognostic analysis, which can help COVID-19
6 screening and finding potential high-risk patients with worse prognosis.

7

1 **Introduction**

2 In Dec. 2019, the novel coronavirus disease 2019 (COVID-19) occurred in
3 Wuhan, China and became a global health emergency very fast with more than
4 170,000 people infected [1-3]. Due to its high infection rate, fast diagnosis and
5 optimized medical resource assignment in epidemic areas are urgent. Accurate and
6 fast diagnosis of COVID-19 can help isolating infected patients to slow the spread of
7 this disease. On the other hand, in epidemic area, insufficient medical resources have
8 become a big challenge [4]. Therefore, finding high-risk patients with worse
9 prognosis for prior medical resources and special care is crucial in the treatment of
10 COVID-19.

11 Currently, reverse transcription polymerase chain reaction (RT-PCR) is used
12 as the gold truth for diagnosing COVID-19. However, the limited sensitivity of RT-
13 PCR and the shortage of testing kits in epidemic areas increase the screening burden,
14 and many infected people are thereby not isolated immediately [5, 6]. This accelerates
15 the spread of COVID-19. On the other hand, due to the lack of medical resources,
16 many infected patients cannot receive immediate treatment. In this situation, finding
17 high-risk patients with worse prognosis for prior treatment and early prevention is
18 important. Consequently, fast diagnosis, finding high-risk patients with worse
19 prognosis are very helpful for the control and management of COVID-19.

20 In recent studies, radiological findings demonstrated that computed
21 tomography (CT) has great diagnostic and prognostic value for COVID-19. For
22 example, CT showed much higher sensitivity than RT-PCR in diagnosing COVID-19
23 [5, 6]. For patients with COVID-19, bilateral lung lesions consisting of ground-glass
24 opacities (GGO) were frequently observed in CT images [6-8]. Even in asymptomatic
25 patients, abnormalities and changes were observed in serial CT [9, 10]. As a common

1 diagnostic tool, CT is easy and fast to acquire without adding much cost. Building a
2 sensitive diagnostic tool using CT image can accelerate the diagnostic process and is
3 complementary to RT-PCR. On the other hand, predicting personalized prognosis
4 using CT image can identify the potential high-risk patients who are more likely to
5 become severe and need urgent medical resources.

6 Deep learning (DL) as an artificial intelligence method, has shown promising
7 results in assisting lung disease analysis using CT images [11-14]. Benefiting from
8 the strong feature learning ability, DL can mine features that are related to clinical
9 outcomes from CT images automatically. Features learned by DL models can reflect
10 high-dimensional abstract mappings which are difficult for human to sense but are
11 strongly associated with clinical outcomes. Different from the published DL models
12 [15, 16], we aim to provide a fully automatic DL system for COVID-19 diagnostic
13 and prognostic analysis. Without requiring any human-assisted annotation, this novel
14 DL system is fast and robust in clinical use. Moreover, we collected a large multi-
15 regional dataset for training and validating the proposed DL system, including 1266
16 patients (471 had follow-up) from six cities or provinces. Notably, different with
17 many studies using transfer learning from natural images. We collected a large
18 auxiliary dataset including 4106 patients with chest CT images and gene information
19 to pre-train the DL system, aiming at making the DL system learn lung features that
20 can reflect the association between micro-level lung functional abnormalities and
21 chest CT images.

1 **Methods**

2 **Study design and participants**

3 The institutional review board of the seven hospitals (supplementary methods
4 1) approved this multi-regional retrospective study and waived the need to obtain
5 informed consent from the patients. In this study, we collected two datasets: COVID-
6 19 dataset (n=1266) and CT-EGFR dataset (n=4106). In the COVID-19 dataset, 1266
7 patients were finally included who met the following inclusion criteria: (i) RT-PCR
8 confirmed COVID-19; (ii) lab-confirmed other types of pneumonia before Dec. 2019;
9 (iii) have non-contrast enhanced chest CT at diagnosis time. Since RT-PCR has a
10 relatively high false-negative rate, we collected other types of pneumonia before Dec.
11 2019 when the COVID-19 did not show up to guarantee the diagnosis of typical
12 pneumonia are correct. In the COVID-19 dataset, patients from Wuhan city and
13 Henan province formed the training set; patients from Anhui province formed the
14 external validation set 1; patients from Heilongjiang province formed the validation
15 set 2; patients from Beijing formed the validation set 3; patients from Huangshi city
16 formed the validation set 4 (figure 1).

17 In the CT-EGFR dataset, 4106 patients with lung cancer were finally included
18 who met the following criteria: (i) epidermal growth factor receptor (EGFR) gene
19 sequencing was obtained; (ii) non-contrast enhanced chest CT data obtained within 4
20 weeks before EGFR gene sequencing. The CT-EGFR dataset was used for auxiliary
21 training of the DL system, making the DL system learn lung features automatically.
22 CT scanning parameters about the COVID-19 and CT-EGFR datasets were available
23 in supplementary methods S1.

1 For prognostic analysis, 471 patients with COVID-19 and regular follow-up
2 for at least 5 days were used. We defined the prognostic end event as the hospital-stay
3 time which is counted from the diagnosis of COVID-19 to the time when the patient
4 is allowed to discharge hospital (supplementary methods S2). A short hospital-stay
5 time corresponds to good prognosis, and a long hospital-stay time means worse
6 prognosis. Patients with long hospital-stay time take longer time to recover, and are
7 defined as high-risk patients in this study. These patients need prior medical resources
8 and special care since they are more likely to become severe.

9 The training set was used to train the proposed DL system; the validation set 1
10 and 2 were used to evaluate the diagnostic performance of the DL system; and the
11 validation set 3 and 4 were used for evaluating the prognostic performance of the DL
12 system.

13 **The fully automatic deep learning system for COVID-19 diagnostic and** 14 **prognostic analysis**

15 The proposed DL system includes three parts: automatic lung segmentation,
16 non-lung area suppression, and COVID-19 diagnostic and prognostic analysis. In this
17 DL system, two DL networks were involved: DenseNet121-FPN for lung
18 segmentation in chest CT image, and the proposed novel COVID-19Net for COVID-
19 19 diagnostic and prognostic analysis. DL is a family of hierarchical neural networks
20 that aim at learning the abstract mapping between raw data to the desired clinical
21 outcome. The computational units in DL model are defined as layers and they are
22 integrated to simulate the inference process of human brain. The main computational
23 formulas are convolution, pooling, activation and batch normalization as defined in
24 the supplementary methods S3.

1 **Automatic lung segmentation**

2 Routinely used chest CT image includes some non-lung areas (muscle, heart,
3 et al.) and blank space outside body. To focus on analyzing lung area, we used a fully
4 automatic DL model (DenseNet121-FPN) [17, 18] to segment lung areas in chest CT
5 image. This model is pre-trained using 1.4 million natural images, and fine-tuned on
6 VESSEL12 dataset [19] (supplementary methods S4).

7 Through this automatic lung segmentation procedure, we acquired the lung
8 mask in CT image. However, some inflammatory tissues attaching to lung wall may
9 be excluded falsely by the DenseNet121-FPN model. To increase the robustness of
10 the DL system, we used the cubic bounding box of the segmented lung mask to crop
11 lung areas in CT image, and defined this cubic lung area as lung-ROI (figure 2). In
12 this lung-ROI, all inflammatory tissues and the whole lung were correctly reserved,
13 and most areas outside of lung were eliminated.

14 **Non-long area suppression**

15 After the above processing, some non-lung tissues or organs (e.g., spine, heart)
16 inside the lung-ROI may also exist. Consequently, we proposed a non-lung area
17 suppression operation to suppress the intensities of non-lung areas inside the lung-
18 ROI (supplementary methods S4). Finally, the lung-ROI is standardized by z-score
19 normalization, and resized to the size of 48×240×360 for further process.

20 **Deep learning model for COVID-19 diagnosis and prognosis**

21 After non-lung area suppression operation, the standardized lung-ROI is sent
22 into the COVID-19Net for diagnostic and prognostic analysis. In figure 2, we
23 illustrated the topological structure of the proposed novel COVID-19Net
24 (supplementary table S1). This DL model used DenseNet-like structure [17],

1 consisting of four dense blocks, where each dense block is multiple stacks of
2 convolution, batch normalization, and ReLU activation layers. Inside each dense
3 block, we used dense connection to consider multi-level image information. At the
4 end of the last convolutional layer, we used global average pooling to generate the 64-
5 dimensional DL features. Finally, the output neuron is fully connected to the DL
6 features to predict the probability of the input patient has COVID-19.

7 To enable the COVID-19Net learn discriminative features associated with
8 COVID-19, a large training set is needed. Consequently, we proposed a two-step
9 transfer learning process. Firstly, we proposed an auxiliary training process use our
10 collected large CT-EGFR dataset (4106 patients) as illustrated in figure 2. In this
11 auxiliary training process, we trained the COVID-19Net to predict EGFR mutation
12 status (EGFR-mutant or EGFR wild type) use the lung-ROI [11]. Benefitting from the
13 large CT-EGFR dataset, the COVID-19Net learned CT features that can reflect the
14 associations between micro-level lung functional abnormality and macro-level CT
15 images.

16 In the second training process, we transferred the pre-trained COVID-19Net to
17 the COVID-19 dataset to specifically mine lung characteristics associated with
18 COVID-19. After iterative training process in the COVID-19 dataset (supplementary
19 methods S5), the COVID-19Net can predict a probability of the input patient being
20 infected with COVID-19; this probability was defined as DL score in this study.

21 To predict personalized prognosis for patient with COVID-19, we extracted
22 the 64-dimensional DL feature from the COVID-19Net to build a prognostic
23 prediction model. Firstly, we combined the 64-dimensional DL feature and clinical
24 features (age, sex, and comorbidity) to construct a combined feature vector.
25 Afterwards, we used stepwise method to select prognostic features. These selected

1 features were then used to build a multivariate Cox proportional hazard (CPH) model
2 to predict the hazard of the patient needing a long hospital-stay time to recover.

3 **Visualization of lung features learned by the DL system**

4 Through the two-step transfer learning technique, the DL system learned lung
5 features from CT images of 4815 patients. To further understand the inference process
6 of the DL system, we used DL visualization algorithm to analyze features learned by
7 the COVID-19Net from two perspectives: 1) visualizing DL-discovered suspicious
8 lung area that contribute most for identifying COVID-19 for the DL system; 2)
9 visualizing the feature patterns extracted by hierarchical convolutional layers in the
10 COVID-19Net (supplementary methods S6, S7).

11 **Statistical analysis**

12 Area under the receiver operating characteristic (ROC) curve (AUC), accuracy,
13 sensitivity, and specificity were used to assess the performance of the DL system in
14 diagnosing COVID-19. Kaplan-Meier analysis and log-rank test were used to evaluate
15 the performance of the DL system for prognostic analysis. The implementation of the
16 DL system used the Keras 2.0.0 toolkit and Python 2.7.

17

1 **Results**

2 Clinical characteristics of patients in the COVID-19 dataset were presented in
3 table 1. This dataset was collected from six cities or provinces including Wuhan in
4 China.

5 **Diagnostic performance of the DL system**

6 Table 2 and figure 3 illustrated the diagnostic performance of the DL system.
7 In the training set, the DL system showed good diagnostic performance (AUC=0.90).
8 This performance was further confirmed in the two external validation sets
9 (AUC=0.87 and 0.88). The good performance in the validation cohorts indicated that
10 the DL system generalized well on diagnosing COVID-19 of unseen new patients.
11 Meanwhile, we illustrated the ROC curves of the DL system in the three sets in figure
12 3a. The DL score revealed a significant difference between COVID-19 and other
13 pneumonia groups in the three sets ($p<0.0001$).

14 In other types of pneumonia, viral pneumonia has similar radiological
15 characteristics to COVID-19, and therefore is more difficult to identify.
16 Consequently, we performed a stratified analysis in the validation set 2. Table 1
17 indicated that the DL system also achieved good results in distinguish COVID-19 to
18 other viral pneumonia (AUC=0.86).

19 **Prognostic performance of the DL system**

20 In the COVID-19 dataset, 471 patients had follow-up for 5+ days. Through the
21 stepwise prognostic feature selection, 3 features were selected (supplementary table
22 S2). These selected prognostic features were fed into the multivariate CPH model to
23 predict a hazard value for each patient. We used median value of the hazards in the
24 training set as cut-off value to stratify patients into high-risk and low-risk groups. This

1 cut-off value was also applied to the validation set 3 and 4. Kaplan-Meier analysis in
2 figure 4 demonstrated that patients in high-risk and low-risk groups had significant
3 difference in hospital-stay time in the three datasets ($p < 0.0001$, $p = 0.013$, and $p = 0.014$,
4 log-rank test).

5 For a given patient, if the DL system predicts him/her as COVID-19, the DL
6 system predicts a prognostic hazard simultaneously. For the patients who are
7 predicted as high-risk by the DL system, prior medical resources and special care are
8 suggested.

9 **Suspicious lung area discovered by the DL system**

10 Through DL visualization algorithm [20, 21], we are able to visualize the lung
11 area that draws most attention to the DL system. These DL-discovered suspicious
12 lung areas usually demonstrated abnormal characteristics consistent with radiologists'
13 findings. Figure 5 illustrated DL-discovered suspicious lung areas of eight patients
14 with COVID-19. From this figure, we can see that although the input lung-ROI to the
15 DL system includes some non-lung tissues such as muscle and bones, the DL system
16 can always focus on areas inside lung for prediction instead of being disturbed by
17 other tissues.

18 Moreover, the DL-discovered suspicious lung areas showed high overlap with
19 the actual inflammatory areas. In figure 5 a-d, we can see that, although we did not
20 involve any human-annotation in the DL system, the DL system focused on the GGO
21 area automatically for inference. This is consistent with radiologists' experiences that
22 many COVID-19 illustrated GGO features [6, 9]. In figure 5 e-h, the DL-discovered
23 suspicious lung areas distributed on bilateral lung, and mainly focused on lesions with
24 consolidation, GGO, diffuse or mixture patterns. When comparing these DL-

1 discovered suspicious lung areas with actual abnormal lung areas, we found a high
2 overlap and consistent.

3 Although we did not use human annotation (e.g., human annotated ROI) to tell
4 the DL system where to watch, the DL system is capable of discovering the abnormal
5 and important lung areas automatically. This phenomenon could come from the
6 advantage of using the large CT-EGFR dataset and the large COVID-19 dataset for
7 training.

8 **DL feature visualization**

9 Since DL is an end-to-end prediction model that learns abstract mappings
10 between lung CT image and COVID-19 directly, it is helpful to explain the inference
11 process of the DL system. The most important component of DL model is
12 convolutional filter. Therefore, we visualized the 3-dimensional feature patterns
13 extracted by hierarchical convolutional layers in figure 6. The shallow convolutional
14 layer learned low-level simple features such as spindle edges (figure 6a) and wave-
15 like edges (figure 6b). A deeper convolutional layer learned more complex and
16 detailed features (figure 6c). When going deeper, the feature pattern became more
17 abstract and lack visual characteristics (figure 6d) for our eyes. However, these high-
18 level feature patterns are more related to COVID-19 information.

19 At the end of the DL model, the outputs of convolutional filters were
20 compressed into a 64-dimensional vector, which was defined as DL feature. In figure
21 6e, we reduced the 64-dimensional DL feature into two-dimensional space to see the
22 DL feature distribution in the two classes (COVID-19 vs. other types of pneumonia).
23 This figure demonstrated that the two classes distributed separately in the DL feature

- 1 space, which means the DL features are discriminative to identify COVID-19 from
- 2 other types of pneumonia.

1 **Discussion**

2 In this study, we proposed a novel fully automatic DL system using raw chest
3 CT image to help COVID-19 diagnostic and prognostic analysis. To let the DL
4 system mine lung features automatically without involving any time-consuming
5 human annotation, we used a two-step transfer learning strategy. Firstly, we collected
6 4106 lung cancer patients with both CT image and EGFR gene sequencing. Through
7 training in this large CT-EGFR dataset, the DL system learned hierarchical lung
8 features that can reflect the associations between chest CT image and micro-level lung
9 functional abnormality. Afterwards, we collected a large multi-regional COVID-19
10 dataset (n=1266) from 6 cities or provinces to train and validate the diagnostic and
11 prognostic performance of the DL system.

12 The good diagnostic and prognostic performance of the DL system illustrates
13 that DL could be helpful in the epidemic control of COVID-19 without adding much
14 cost. Given a suspected patient, CT scanning can be acquired within minutes.
15 Afterwards, this DL system can be applied to predict the probability of the patient has
16 COVID-19. If the patient is diagnosed as COVID-19, the DL system also predicts
17 his/her prognostic situation simultaneously, which can be used to find potential high-
18 risk patients who need urgent medical resources and special care. More importantly,
19 this DL system is fast and does not require human-assisted image annotation, which
20 increases its clinical value and become more robust. For a typical chest CT scan of a
21 patient, the DL system takes less than ten seconds for prognostic and diagnostic
22 prediction.

23 During building and training the DL system, we did not involve any human
24 annotation to tell the system where the inflammatory area was. However, the DL
25 system managed to automatically discover the important features that are strongly

1 associated with COVID-19. In figure 5, we visualized the DL-discovered suspicious
2 lung areas that were used by the DL system for inference. These DL-discovered
3 suspicious lung areas have high overlap with the actual inflammatory areas that are
4 used by radiologists for diagnosis. In previous studies, some radiological features
5 such as GGO, crazy-paving pattern, and bilateral involvement are reported to be
6 important for diagnosing COVID-19 [7]. In the DL-discovered suspicious lung areas,
7 we also observed these radiological features. This demonstrates that the high-
8 dimensional features mined by the DL system can probably reflect these reported
9 radiological finding.

10 Despite the good performance of the DL system, this study has several
11 limitations. First, there are other prognostic end events such as death or admission to
12 intensive care unit, and they were not considered in this study. Second, the
13 management of severe and mild COVID-19 are different, thereby, explore prognosis
14 of COVID-19 in these two groups separately should be helpful.

15

1 **Contributors**

2 YZ and JT conceived and designed the study. SW implemented the DL system
3 and wrote the paper. QW, YZ, and LW contributed to the data process and analysis.
4 MN, HY, WG, YB, XQ, LL, XL, MW, HL, and WL contributed to data collection.

5 **Acknowledgments**

6 This paper is supported by the National Natural Science Foundation of China
7 under Grant Nos. 81930053 and 81227901, the National Key R&D Program of China
8 under Grant Nos. 2017YFA0205200. We thank all the colleagues in CAS key
9 laboratory of Molecular Imaging, and collaborative hospitals for data collection.

10 **Competing interests:** We declare no competing interests.

11

1 **References**

2

3 1. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z,

4 Xiong Y. Clinical characteristics of 138 hospitalized patients with 2019 novel

5 coronavirus–infected pneumonia in Wuhan, China. *JAMA* 2020.

6 2. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KS, Lau EH,

7 Wong JY. Early transmission dynamics in Wuhan, China, of novel coronavirus–

8 infected pneumonia. *New England Journal of Medicine* 2020.

9 3. Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T.

10 Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia

11 in Wuhan, China: a single-centered, retrospective, observational study. *The Lancet*

12 *Respiratory Medicine* 2020.

13 4. Ji Y, Ma Z, Peppelenbosch MP, Pan Q. Potential association between COVID-

14 19 mortality and health- care resource availability. *the Lancet Global Health* 2020.

15 5. Xie X, Zhong Z, Zhao W, Zheng C, Wang F, Liu J. Chest CT for typical 2019-

16 nCoV pneumonia: relationship to negative RT-PCR testing. *Radiology* 2020: 200343.

17 6. Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, Tao Q, Sun Z, Xia L.

18 Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-

19 19) in China: A Report of 1014 Cases. *Radiology*: 0(0): 200642.

20 7. Zhang S, Li H, Huang S, You W, Sun H. High-resolution CT features of 17

21 cases of Corona Virus Disease 2019 in Sichuan province, China. *European*

22 *Respiratory Journal* 2020.

23 8. Wang L, Gao Y-h, Zhang G-J. The clinical dynamics of 18 cases of COVID-

24 19 outside of Wuhan, China. *European Respiratory Journal* 2020.

- 1 9. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, Fan Y, Zheng C.
2 Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China:
3 a descriptive study. *The Lancet Infectious Diseases* 2020.
- 4 10. Lee EY, Ng M-Y, Khong P-L. COVID-19 pneumonia: what has CT taught us?
5 *The Lancet Infectious Diseases* 2020.
- 6 11. Wang S, Shi J, Ye Z, Dong D, Yu D, Zhou M, Liu Y, Gevaert O, Wang K,
7 Zhu Y. Predicting EGFR mutation status in lung adenocarcinoma on computed
8 tomography image using deep learning. *European Respiratory Journal* 2019; 53(3):
9 1800986.
- 10 12. Walsh SL, Calandriello L, Silva M, Sverzellati N. Deep learning for
11 classifying fibrotic lung disease on high-resolution computed tomography: a case-
12 cohort study. *The Lancet Respiratory Medicine* 2018; 6(11): 837-845.
- 13 13. Walsh SL, Humphries SM, Wells AU, Brown KK. Imaging research in
14 fibrotic lung disease; applying deep learning to unsolved problems. *The Lancet*
15 *Respiratory Medicine* 2020.
- 16 14. Angelini E, Dahan S, Shah A. Unravelling machine learning: insights in
17 respiratory medicine. *European Respiratory Journal* 2019; 54(6).
- 18 15. Wang S, Kang B, Ma J, Zeng X, Xiao M, Guo J, Cai M, Yang J, Li Y, Meng
19 X. A deep learning algorithm using CT images to screen for Corona Virus Disease
20 (COVID-19). *medRxiv* 2020.
- 21 16. Xu X, Jiang X, Ma C, Du P, Li X, Lv S, Yu L, Chen Y, Su J, Lang G. Deep
22 Learning System to Screen Coronavirus Disease 2019 Pneumonia. *arXiv preprint*
23 *arXiv:200209334* 2020.

- 1 17. Huang G, Liu Z, Van Der Maaten L, Weinberger KQ. Densely connected
2 convolutional networks. In: Proceedings of the IEEE conference on computer vision
3 and pattern recognition; 2017; 2017. p. 4700-4708.
- 4 18. Lin T-Y, Dollár P, Girshick R, He K, Hariharan B, Belongie S. Feature
5 pyramid networks for object detection. In: Proceedings of the IEEE conference on
6 computer vision and pattern recognition; 2017; 2017. p. 2117-2125.
- 7 19. Rudyanto RD, Kerkstra S, Van Rikxoort EM, Fetita C, Brillet P-Y, Lefevre C,
8 Xue W, Zhu X, Liang J, Öksüz İ. Comparing algorithms for automated vessel
9 segmentation in computed tomography scans of the lung: the VESSEL12 study.
10 *Medical image analysis* 2014; 18(7): 1217-1232.
- 11 20. Selvaraju RR, Cogswell M, Das A, Vedantam R, Parikh D, Batra D. Grad-
12 CAM: Visual Explanations from Deep Networks via Gradient-Based Localization. In:
13 2017 IEEE International Conference on Computer Vision (ICCV); 2017 22-29 Oct.
14 2017; 2017. p. 618-626.
- 15 21. Kotikalapudi Rac. keras-vis. GitHub, <https://github.com/raghakot/keras-vis>,
16 2017.
- 17

1 **Tables**

2 **Table 1. Clinical characteristics of patients.**

	Training set (n = 709)	Validation 1 (n = 226)	Validation 2 (n=161)	Validation 3 (n=53)	Validation 4 (n = 117)
Region (city or province)	Wuhan city, and Henan	Anhui	Heilongjiang	Beijing	Huangshi city
Type					
COVID-19	560	102	92	53	117
Bacterial pneumonia	127	119	25	0	0
Mycoplasma pneumonia	11	5	15	0	0
Viral pneumonia	0	0	29	0	0
Fungal pneumonia	11	0	0	0	0
Sex					
Male	337	131	108	25	60
Female	372	95	53	28	57
Age	50.52±18.91	49.15±18.44	58.44±16.19	50.26±19.29	47.67±14.20
Comorbidity					
Any	204	NA	NA	16	27
Diabetes	45			2	12
Hypertension	120			10	12
Cerebrovascular disease	18			1	0
Cardiovascular disease	21			5	9
Malignancy	19			0	1
COPD	10			1	2
Pulmonary tuberculosis	6			1	0
Chronic kidney disease	10			0	2
Chronic liver disease	16			3	2
Follow-up > 5 days	301	NA	NA	53	117

3 AUC is area under the receiver operating characteristic curve.

4

1 **Table 2. Diagnostic performance of the DL system.**

	Training (n=709)	Validation 1 (n=226)	Validation 2 (n=161)	Validation 2-viral (n=120)
AUC (95% CI)	0.90 (0.89-0.91)	0.87 (0.86-0.89)	0.88 (0.86-0.90)	0.86 (0.83, 0.89)
Accuracy (%)	81.24	78.32	80.12	85.00
Sensitivity (%)	78.93	80.39	79.35	79.35
Specificity (%)	89.93	76.61	81.16	71.43

2 AUC is area under the receiver operating characteristic curve.

3 Validation 2-viral is a stratified analysis using the patients with COVID-19 and viral pneumonia in
4 the validation set 2.

5

1 **Figure legends**

2 **Figure 1.** Datasets used in this study.

3 A total of 5372 patients with CT images from 7 cities or provinces were enrolled in this study. The
4 auxiliary training set includes 4106 patients with lung cancer and EGFR gene mutation status
5 information, and is used to pre-train the COVID-19Net to learn lung features from CT images.
6 The training set includes 709 patients from Wuhan city and Henan province. The external
7 validation set 1 (226 patients) from Anhui province, and the external validation set 2 (161 patients)
8 from Heilongjiang province are used to test the diagnostic performance of the DL system. The
9 external validation set 3 (53 patients with COVID-19) from Beijing, and the external validation set
10 4 (117 patients with COVID-19) from Huangshi city are used to evaluate the prognostic
11 performance of the DL system.

12

13 **Figure 2.** Illustration of the proposed DL system.

14 Given the chest CT scanning of a patient, the DL system predicts the probability of the patient has
15 COVID-19 and the prognosis of this patient directly without any human-annotation. The DL
16 system includes three parts: automatic lung segmentation (DenseNet121-FPN), non-lung area
17 suppression, and COVID-19 diagnostic and prognostic analysis (COVID-19Net). To let the
18 COVID-19Net learn lung features from large dataset, we used the auxiliary training process for
19 pre-training, which trained the DL network to predict EGFR gene mutation status using CT
20 images of 4106 patients. The dense connection in this figure means each convolutional layer is
21 connected to all of its previous convolutional layers inside the same dense block.

22

23 **Figure 3.** Diagnostic performance of the DL system.

24 **a).** ROC curves of the DL system in the training set and the two independent external validation
25 sets. Validation 2-viral is a stratified analysis using the patients with COVID-19 and viral
26 pneumonia in the validation set 2. **b).** AUC and distribution of the training set and the two external
27 validation datasets.

28

1 **Figure 4.** Kaplan-Meier analysis of the prognostic performance of the DL system.

2 Vertical lines in this figure represents censored data.

3

4 **Figure 5.** DL-discovered suspicious lung area.

5 **(a)-(h)** are CT images of eight patients with COVID-19. The first and the third rows are CT

6 images of the patients (these CT images are processed by the DL system). The second and the

7 fourth rows are heat maps of the DL-discovered suspicious lung area. In the heat map, areas with

8 bright red color are more important than dark blue areas.

9

10 **Figure 6.** DL feature visualization.

11 **(a)-(d)** are four 3-dimensional (3D) convolutional filters from different convolutional layers. **(e)** is

12 the distribution of patients in the 64-dimensional DL feature space. For display convenience, the

13 64-dimensional DL feature space is reduced to 2-dimensional by principle component analysis

14 algorithm.

15

External validation 3

n=53, Beijing



CT image



all with COVID-19
follow-up > 5 days

External validation 2

n=161, Heilongjiang



CT image



COVID-19: 92
other pneumonia: 69

Auxiliary training

n=4106, Sichuan



CT image



EGFR gene
mutation status

mutant: 2096
wild type: 2010

Training

n=709, Wuhan, and Henan



CT image



COVID-19: 560
other pneumonia: 149



follow-up > 5 days: 301

External validation 1

n=226, Anhui



CT image



COVID-19: 102
other pneumonia: 124

External validation 4


n=117, Huangshi



CT image




all with COVID-19
follow-up > 5 days



bioRxiv preprint doi: <https://doi.org/10.1101/2020.03.24.20042977>; this version posted March 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.


CT image input



medRxiv preprint doi: <https://doi.org/10.1101/2020.03.24.20042317>; this version posted March 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

COVID-19Net: COVID-19 prognostic and diagnostic analysis model

Prognostic and diagnostic outcome




- 3D convolution (kernel=3x3x3)
- 3D convolution (kernel=1x1x1)
- batch normalization
- deep learning feature
- max pooling (window, stride=2)
- global average pooling
- dense connection

Auxiliary training process



Use CT and gene data of 4106 lung cancer patients to pre-train the COVID-19Net


CT image of patients with lung cancer




EGFR gene mutation status

Learn lung features that can reflect micro-level lung functional abnormality













	0	6	12	18	24	30
Low risk	150	141	93	39	12	0
High risk	151	141	89	43	15	5
	Number at risk					



	0	6	12	18	24	30
Low risk	32	32	15	5	0	0
High risk	21	21	14	6	1	0
	Number at risk					



	0	6	12	18	24	30
Low risk	37	37	25	6	1	0
High risk	80	80	62	23	4	0
	Number at risk					











(a)

(b)

(c)

(d)



(e)

(f)

(g)

(h)

medRxiv preprint doi: <https://doi.org/10.1101/2020.03.14.20042317>; this version posted March 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

